Tomuzotuximab - Glycotope

Drug Profile

Tomuzotuximab - Glycotope

Alternative Names: CetuGEX; Cetuximab biobetter - Glycotope; GT-MAB 5.2-GEX

Latest Information Update: 08 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GLYCOTOPE
  • Developer Glycotope
  • Class Antineoplastics; Biobetters; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Head and neck cancer
  • Phase I/II Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Renal cancer
  • Phase I Solid tumours

Most Recent Events

  • 02 Nov 2017 Phase-I clinical trials in Solid tumours (Metastatic disease, Combination therapy, Second-line therapy or greater, Late-stage disease) in Germany, Spain (IV) (NCT03360734)
  • 20 May 2016 Cetuximab biobetter is still in phase II trials for Head and neck cancer (Late-stage disease, Metastatic disease, Recurrent) in Belgium, Germany, France, Italy, Poland, Romania and Spain
  • 20 May 2016 Phase-I/II development for Colorectal cancer, Non-small cell lung cancer, Gastric cancer and Renal cancer is ongoing in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top